Cancer biosensor design · Founded 2025

Earlier cancer detection starts with better-designed biosensors.

OncoSensor turns a published review of cancer biosensors into a design framework for point-of-care tests. It links four dimensions, Material, Mechanism, Modeling and Measurement, so sensor developers can move from the lab towards real-world use.

See the solutionView the results
4MMaterial, Mechanism, Modeling, Measurement
5transduction methods compared
6cancer types reviewed in depth
The 4M framework At a glance
MaterialWhat the sensing surface is made of
M1
MechanismHow a biomarker becomes a signal
M2
Modeling and MeasurementHow the signal is predicted and read
M3 · M4
Why it matters: The review finds that a cohesive framework joining these four dimensions is often missing from biosensor research.
The problem

Biosensor research is rich but fragmented.

Micro and nanoscale chip fabrication has transformed biosensors, yet few reach patients at scale.

No shared framework

Work on materials, mechanisms, modelling and measurement is often done in isolation.

Hard to compare

Point-of-care sensing methods differ widely, which makes it hard to judge which is practical for a given test.

Stalled commercialisation

The review identifies limitations that hinder biosensors from global commercialisation.

Our solution

One framework from material to measurement.

OncoSensor organises biosensor design around the 4M dimensions and a comparative view of sensing methods, so each design decision is made with the end test in mind.

Design

Material and mechanism

5transduction routes reviewed
  • Electrochemical and optical
  • Photoelectrochemical and piezoelectric
  • Aptamer-based sensing
Target

Cancer biomarkers

6cancer types covered in detail
  • Lung, liver and gastric
  • Breast, prostate and cervical
  • Markers such as PSA, CEA, AFP, HER-2 and CA-125
Delivery

Point-of-care readiness

MEMSintegrated chips as the platform direction
  • Comparative analysis of point-of-care methods
  • Categorised by fabrication process
  • Limitations mapped before scale-up
How it works

How it works

A four-step design path that follows the 4M framework.

  1. 1

    Material

    Choose the sensing material and fabrication process for the chip.

    nanomaterialsMEMS
  2. 2

    Mechanism

    Pick the transduction route that turns biomarker binding into a signal.

    electrochemicalopticalaptamer
  3. 3

    Modeling

    Model how the sensor should respond before building it.

    modelling
  4. 4

    Measurement

    Read and compare performance in a point-of-care format.

    point-of-carebiomarkers
Results

What the review covers

This is a review of published biosensor research, not a new laboratory or clinical study. It synthesises the 4M dimensions, compares sensing methods and assesses barriers to commercialisation.

4Mdimensions joined in one framework
5transduction methods compared
6cancer types with dedicated sections
Reviewevidence type

Source: Gupta et al., RSC Advances 15(10), 8019-8052 (2025). doi:10.1039/d4ra08212e

Who it's for

Who it is for

Teams designing the next generation of cancer tests.

Biosensor developers

  • A structured design checklist
  • Comparison of transduction routes
  • Known barriers to scale

Diagnostics companies

  • Point-of-care method comparison
  • Biomarker landscape by cancer type
  • Commercialisation risks up front

Researchers and students

  • One map of a broad field
  • Links between material and measurement
  • Gaps for new work
Where we are

What we do not claim

Honest limits at this stage.

A review, not a device

The evidence is a synthesis of existing literature. OncoSensor has not yet built or validated its own sensor.

No diagnostic claims

Nothing here is a cleared or approved diagnostic test.

Barriers remain

The review itself identifies limitations that still hold biosensors back from wide commercial use.

The team

The team

Founded in 2025 by the research team behind the 4M review of cancer biosensors.

SG

Sachin Gupta

Co-author of the OncoSensor research.

VM

Vijay Mishra

Co-author of the OncoSensor research.

AA

Alaa A. A. Aljabali

Co-author of the OncoSensor research.

AA

Aqel Albutti

Co-author of the OncoSensor research.

RK

Rajeev Kanday

Co-author of the OncoSensor research.

ME

Mohammad K.K. El-Tanani

Co-author of the OncoSensor research.

YM

Yachana Mishra

Co-author of the OncoSensor research.

Frequently asked questions

What are the 4Ms?

Material, Mechanism, Modeling and Measurement: the four dimensions the review brings together for biosensor design.

Which cancers does it cover?

The review has sections on lung, liver, gastric, breast, prostate and cervical cancer detection.

Is OncoSensor a test I can buy?

No. It is a research-stage design framework based on a published review.

Why point-of-care?

The review compares point-of-care sensing methods because tests that work outside central labs could support earlier detection.

What holds biosensors back?

The review critically assesses limitations that hinder global commercialisation, and OncoSensor aims to design around them.

The research

Peer-reviewed science behind OncoSensor.

Read the full study behind the product.

Read the paper

Gupta, S., Mishra, V., Aljabali, A. A. A., Albutti, A., Kanday, R., El-Tanani, M., & Mishra, Y. (2025). Breaking barriers in cancer diagnosis: Unveiling the 4Ms of biosensors. RSC Advances, 15(10), 8019–8052. https://doi.org/10.1039/d4ra08212e

https://doi.org/10.1039/d4ra08212e